A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty
NCT ID: NCT02518269
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
360 participants
INTERVENTIONAL
2015-05-04
2030-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In addition, the purpose of the study is also to evaluate the safety and effectiveness of patients who received G7 Acetabular system in conjunction with Echo BiMetric stem in primary total hip arthroplasty.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
G7 Dual Mobility System Used in Total Hip Arthroplasty for the Treatment of Femoral Neck Fracture
NCT04031209
Prospective Clinical Follow-up of the Echo Bi-Metric Microplasty Stem for Total Hip Arthroplasty
NCT04326010
Fixation of OsseoTi™ Porous Structure Versus PPS (Porous Plasma Spray) Coating on the G7™ Acetabular Component for Primary Total Hip Arthroplasty
NCT02316704
G7 Dual Mobility With Vivacit-E or Longevity PMCF
NCT05548972
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
NCT04754087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PURPOSE:To compare three commonly used contemporary bearings in Total Hip Arthroplasty (THA). In addition, to evaluate the safety and effectiveness of the G7 Cups and Echo BiMetric Stem in THA.
OUTCOME MEASURES: Osteolysis, clinical outcomes, patient satisfaction, intraoperative/surgical data, implant positioning, survivor ship, and adverse events.
POPULATION: 360 hips (240 will have CT scan for analysis of osteolysis).
ELIGIBILITY: Patients who meet inclusion and exclusion criteria defined in this protocol.
DURATION: All patients will be followed at 3 months, 1, 2, 5, 7 and 10 year postoperatively. Assuming the enrollment will be completed 18 months. The total study duration will be 11.5 years.
STUDY GROUPS/TREATMENTS
Group 1 - G7 Metal-on-Polyethylene (MoP) (Arcom XL) + Echo BiMetric Group 2 - G7 Metal-on-Polyethylene (MoP) (E1) + Echo BiMetric Group 3 - G7 Ceramic-on-Ceramic (CoC) + Echo BiMetric The study's primary efficacy endpoint will include the difference in osteolytic volume at 5 years postoperatively measured by Computertomografi (CT) scan.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
G7 MoP (Arcom XL) + Echo BiMetric
Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an Arcom Xl liner and a metal head
Hip Arthroplasty
Hip Arthroplasty comparing 3 different bearings.
G7 MoP (E1) + Echo BiMetric
Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
Hip Arthroplasty
Hip Arthroplasty comparing 3 different bearings.
G7 CoC + Echo BiMetric
Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive a ceramic liner and a ceramic head
Hip Arthroplasty
Hip Arthroplasty comparing 3 different bearings.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hip Arthroplasty
Hip Arthroplasty comparing 3 different bearings.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients determined to be suitable for uncemented fixation by investigator
* Patient is skeletally mature.
* Patient qualifies for primary unilateral total hip arthroplasty (THA) based on physical exam and medical history including the following:
* Osteoarthritis (OA)
* Developmental Dysplasia without subluxation
* Patient is willing and able to provide written informed consent.
* Patient is willing and able to cooperate in the required post-operative therapy.
* Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
Exclusion Criteria
* A prisoner
* Mentally incompetent or unable to understand what participation in the study entails
* A known alcohol or drug abuser
* Anticipated to be non-compliant.
* The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure, or complications in postoperative care.
* The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.
* The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
* The patient is known to be pregnant.
* The patient is unwilling or unable to give informed consent, or to comply with the follow-up program.
* The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.
The patient has had previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated.
* The patient has insufficient bone stock to fix the component. Insufficient bone stock exists (ex: Dorr type C) in the presence of metabolic bone disease (i.e. osteoporosis), cancer, and radiation.
* Estimated cup size smaller than 48 or stem size smaller than 7
* The patient has known local bone tumors in the operative hip.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zimmer Biomet
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anders Troelsen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hvidovre University Hospital
Henrik Malchau, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Sahlgrenska University Hospital
Ville Remes, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Jokilaakson Terveys Oy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalborg University Hospital
Aalborg, , Denmark
Hvidovre hospital
Copenhagen, , Denmark
Jokilaakson Terveys Oy
Jämsä, , Finland
Turku university hospital
Turku, , Finland
Sahlgrenska University Hospital
Gothenburg, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ORTHO.CR.GH33
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.